Orthopedic surgery or orthopedics (also spelled orthopaedics) is the branch of surgery concerned with conditions involving the musculoskeletal system. Orthopedic surgeons use both surgical and non-surgical means to treat musculoskeletal trauma, sports injuries, degenerative diseases, infections, tumors, and congenital conditions.
U.S. Physical Therapy, Inc., a leading national operator of outpatient physical therapy clinics, has acquired a majority interest in a six clinic physical therapy group located in the mid-Atlantic region. The practice presently sees approximately 55,000 patient visits per year and produces approximately $4.8 million in annual revenue.
El Camino Hospital today announced its first patient implant in the Medtronic CoreValve® U.S. Clinical Trial.
Biomet, Inc., a global leader in the manufacture of orthopedic and biotechnology products, announced today that its subsidiary, Biomet Biologics, LLC, has completed the required 230 subject enrollment for its Recover® Kit clinical trial. This clinical trial studies the use of the Recover® Kit device, which produces autologous platelet-rich plasma (PRP) to treat chronic tennis elbow (lateral epicondylitis).
Almost three quarters of hospital emergency department administrators nationwide report that lack of medical specialists at their facilities poses a risk to ER patients – in some cases a very significant risk.
BioMimetic Therapeutics, Inc. announced today the Canadian Intellectual Property Office (CIPO) has allowed patent application No. 2,583,823 titled "Platelet Derived Growth Factor (PDGF) Compositions and Methods of Use Thereof". The new patent will remain in force until October 2025, during which time it will prohibit the marketing of similar or generic versions of the Company's Augment™ orthopedic product line and certain other rhPDGF-BB product formulations.
Orthofix International N.V. today announced an internal reorganization designed to streamline operations within its three Global Business Units: Spine, Orthopedics and Sports Medicine. The Company expects to record a charge related to employee termination benefits of approximately $4.0 million ($2.4 million net of tax, or $0.13 per diluted share) in the fourth quarter of 2010 in connection with the reorganization.
On-X® Life Technologies, Inc., today announced the publication of results of a large, prospective multi-center Canadian trial with the On-X® Prosthetic Heart Valve in the November issue of The Journal of Thoracic and Cardiovascular Surgery.1 According to the results of the report, "The On-X mechanical prosthesis provides favorable intermediate-term results with regard to major thromboembolism, hemorrhage and composites of valve-related complications."
Marin General Hospital has announced a new joint venture that provides a single point of access in Marin for world-class, comprehensive multidisciplinary and cross-disciplinary treatment and management of spine and brain disorders and disease.
CorMatrix Cardiovascular, Inc., an Atlanta-based company dedicated to developing and delivering unique extracellular matrix (ECM) biomaterial devices that harness the body's innate ability to repair damaged cardiovascular tissue, announced today that Franciscan Alliance/St. Francis Heart Center in Indianapolis, Indiana is the first site to enroll a patient in the multi-center clinical trial of the CorMatrix ECM for Pericardial Closure to reduce the incidence of new onset postoperative atrial fibrillation.
Ascension Orthopedics, Inc., a market leader in PyroCarbon orthopedic implants, announces the first implantation of the PyroTITAN™ Humeral Resurfacing Implant in France. The PyroTITAN was implanted in a 68-year-old patient suffering from painful primary arthritis with synovial osteochondromotosis at Imperial Park Clinic in Nice – making it a surgical first in continental Europe. The patient was discharged from the hospital the next day and reported good pain relief 10 days after surgery.
"You'll be back on your feet in no time" is a phrase familiar to anyone who's ever had to spend time in a hospital. Now, a new study has shown that hospitalized elderly patients who literally "get back on their feet" by taking even short walks around a hospital unit tend to leave the hospital sooner than their more sedentary peers.
Researchers from Michigan State University are studying whether pregnancies, specifically cesarean-section deliveries, are linked to a degenerative back disease that affects women three to nine times more often than men.
MMI-USA, a subsidiary of Memometal Technologies S.A., a global orthopaedic manufacturer headquartered in France, announces the limited launch of the new Smart Toe® II Hammertoe Fixation System. The product becomes an important piece of a comprehensive system for forefoot fixation, and reinforces the most widely used franchise of intramedullary implants of this kind in the world.
Hanger Orthopedic Group, Inc. announced today the pricing of the previously announced public offering of 2,000,000 shares of its common stock by Ares Corporate Opportunities Fund, L.P. at a public offering price of $20.00 per share. The transaction is expected to close on December 15, 2010. The shares sold were a portion of the currently outstanding shares issued to Ares in August 2008 in connection with the conversion of all of Hanger's Series A Convertible Preferred Stock into common stock.
New guidelines on exercise for people with diabetes are likely to open some eyes — and, for those who follow them, help prevent or manage diabetes, improve overall health and boost quality of life. A panel of nine experts developed the recommendations, published this month in Medicine & Science in Sports & Exercise, the official journal of the American College of Sports Medicine.
Ellipse Technologies, Inc. announced today that it has received CE-Mark approval of the Company's PRECICETM Limb Lengthening device. Limb Lengthening procedures are used to treat a number of medical conditions, including shortened legs due to congenital abnormalities, major fractures of one of the legs and shortened leg bones due to other medical diseases, such as cancer.
BioMimetic Therapeutics, Inc. today announced it initiated enrollment in a pilot clinical trial to assess the safety and clinical utility of AugmentTM Rotator Cuff Graft for the repair of large rotator cuff tears. The randomized, controlled pilot trial is expected to include enrollment of up to 30 patients.
Orthovita, Inc. , an orthobiologics and biosurgery company, announced today that it received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market Vitoss Bioactive Foam-2X Bone Graft Substitute for use as a non-structural bone void filler for use in the spine, pelvis and extremities. Orthovita expects to launch the newest addition to its bone graft substitute product line by late February or early March of 2011.
The latest advances in the treatment of bleeding and clotting disorders will be presented today at the 52nd Annual Meeting of the American Society of Hematology, focusing on venous thrombeombolism, a potentially life-threatening disorder in which abnormal blood clots form in the veins and restrict the flow of blood. New studies examine risk-prediction models and cutting-edge treatment options for patients with VTE.
Hospital for Special Surgery announced the creation of the Center for Musculoskeletal Outcomes and Patient Oriented Research to translate information collected from an extensive patient population into studies that will guide experts in preventing, diagnosing and treating musculoskeletal disorders.
Terms
While we only use edited and approved content for Azthena
answers, it may on occasions provide incorrect responses.
Please confirm any data provided with the related suppliers or
authors. We do not provide medical advice, if you search for
medical information you must always consult a medical
professional before acting on any information provided.
Your questions, but not your email details will be shared with
OpenAI and retained for 30 days in accordance with their
privacy principles.
Please do not ask questions that use sensitive or confidential
information.
Read the full Terms & Conditions.